Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC

References

• Hamra GB, Richardson DB, Dement J, et al. Lung cancer risk associated with regulated and unregulated chrysotile asbestos fibers. Epidemiology. 2017;28:275–280. doi: 10.1097/EDE.0000000000000597.
   PubMed Web of Science ®Google Scholar
• Hradilova N, Sadilkova L, Palata O, et al. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PloS One. 2017;12:e0171539. doi: 10.1371/journal.pone.0171539.
   PubMed Web of Science ®Google Scholar
• Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11:1663–1668. doi: 10.1517/14712598.2011.627850.
   PubMed Web of Science ®Google Scholar
• Karasaki T, Nagayama K, Kuwano H, et al. An immunogram immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer. J Thorac Oncol. 2017;12:791–803. doi: 10.1016/j.jtho.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Duan SZ, Tsai Y, Keng P, et al. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget. 2015;6:27651–27660. doi: 10.18632/oncotarget.4753.
   PubMedGoogle Scholar
• Tang H, Liao Y, Chen G, et al. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-beta. Med Oncol. 2012;29:2640–2648. doi: 10.1007/s12032-012-0198-8.
   PubMed Web of Science ®Google Scholar
• Tang H, Liao Y, Xu L, et al. Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int J Cancer. 2013;133:2473–2482. doi: 10.1002/ijc.28262.
   PubMed Web of Science ®Google Scholar
• Wei YH, Tang HX, Liao YD, et al. Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer. J Huazhong Univ Sci Technol [Med Sci]. 2015;35:834–841. doi: 10.1007/s11596-015-1515-1.
   PubMed Web of Science ®Google Scholar
• Speirs V, Kerin MJ, Walton DS, et al. Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells. Br J Cancer. 2000;82:1312–1316. doi: 10.1054/bjoc.1999.1097.
   PubMed Web of Science ®Google Scholar
• You S, Li R, Park D, et al. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Therap. 2014;13:606–616. doi: 10.1158/1535-7163.MCT-13-0608.
   PubMed Web of Science ®Google Scholar
• Jeon JH, Kim SK, Kim HJ, et al. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer. Cancer Lett. 2008;272:232–241. doi: 10.1016/j.canlet.2008.07.011.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Carapancea M, Alexandru O, et al. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors. 2007;25:1–8. doi: 10.1080/08977190600702865.
   PubMed Web of Science ®Google Scholar
• Chevalier S, Fourcin M, Robledo O, et al. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. J Biol Chem. 1996;271:14764–14772.
   PubMed Web of Science ®Google Scholar
• Hiney JK, Srivastava VK, Dees WL. Manganese induces IGF-1 and cyclooxygenase-2 gene expressions in the basal hypothalamus during prepubertal female development. Toxicol Sci. 2011;121:389–396. doi: 10.1093/toxsci/kfr057.
   PubMed Web of Science ®Google Scholar
• Huang LH, Hu JQ, Tao WQ, et al. Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells. Eur J Pharmacol. 2010;645:9–13. doi: 10.1016/j.ejphar.2010.06.070.
   PubMed Web of Science ®Google Scholar
• Surin AM, Sharipov RR, Krasil’nikova IA, et al. Disruption of functional activity of mitochondria during MTT assay of viability of cultured neurons. Biochemistry-Moscow+. 2017;82:737–749. doi: 10.1134/S0006297917060104. PubMed PMID: WOS:000403456200010; English.
   PubMed Web of Science ®Google Scholar
• Misharin AV, Morales-Nebreda L, Mutlu GM, et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013;49:503–510. doi: 10.1165/rcmb.2013-0086MA.
   PubMed Web of Science ®Google Scholar
• Shen M, Ren XB. Highlights on immune checkpoint inhibitors in non-small cell lung cancer. Tumor Biol. 2017;39:1010428317695013. doi: 10.1177/1010428317695013
   Google Scholar
• Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers. 2014;6:708–722. doi: 10.3390/cancers6020708.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74. doi: 10.1016/j.smim.2014.01.001.
   PubMed Web of Science ®Google Scholar
• Wang XM, Wang YY, Xiao G, et al. Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway. Oncotarget. 2016;7:30350–30364. doi: 10.18632/oncotarget.8734.
   PubMedGoogle Scholar
• Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 2006;7:273–275. doi: 10.3816/Clc.2006.N.006.
   PubMed Web of Science ®Google Scholar
• Zhou B, Liu J, Wang ZM, et al. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PloS One. 2012;7(8):e43075. doi: 10.1371/journal.pone.0043075.
   PubMed Web of Science ®Google Scholar
• Kita H, Shiraishi Y, Watanabe K, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?. Ann Thorac Cardiovasc Surg. 2011; 17:454–460. doi: 10.5761/atcs.oa.10.01627.
   PubMed Web of Science ®Google Scholar
• Chang CH, Hsiao CF, Yeh YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 2013; 132:1977–1985. doi: 10.1002/ijc.27892.
   PubMed Web of Science ®Google Scholar
• Liao C, Yu ZB, Guo W, et al. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomarkers. 2014;14:469–481. doi: 10.3233/Cbm-140423.
   PubMed Web of Science ®Google Scholar
• Brussino L, Culla B, Bucca C, et al. Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer. J Breath Res 2014;8:027110. doi: 10.1088/1752-7155/8/2/027110.
   PubMed Web of Science ®Google Scholar
• You LK, Liu CY, Tang HX, et al. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment. Curr Pharma Des. 2014;20:2899–2911.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Biersack B, Li YW, et al. Targeted regulation of PI3K/Akt/mTOR/NF-kappa B signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anti-cancer Agent Med Chem. 2013;13:1002–1013.
   PubMed Web of Science ®Google Scholar
• Liu CY, Zhang Z, Tang HX, et al. Crosstalk between IGF-1R and other tumor promoting pathways. Curr Pharma Des. 2014;20:2912–2921.
   PubMed Web of Science ®Google Scholar
• Yi H, Cho HJ, Cho SM, et al. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cancer stem cells. Int J Oncol. 2012;41:310–316. doi: 10.3892/ijo.2012.1447.
   PubMed Web of Science ®Google Scholar
• Liu CC, Lin JH, Hsu TW, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136:547–559. doi: 10.1002/ijc.29033.
   PubMed Web of Science ®Google Scholar